Amarin Corp Plc (AMRN)

[lizzy241]

maximizing U.S. Cash Flow Through Streamlined Model: Amarin will maintain VASCEPA as a cost-effective option to generics while implementing a reduction in force of all U.S. sales force positions and approximately 30% of non-sales roles. Amarin will retain its managed care and trade organization to support these efforts. The Company will continue to explore innovative approaches to driving revenue as well as the timing of an

authorized generic version of VASCEPA

to maintain its leadership position in the icosapent ethyl (IPE) market.

It's about time they offered a generic version of Vascepa.